Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Tohoku University

Senju Pharmaceutical Co., Ltd.

Takashi Imada

Nobuhiro Suzuki

Tsuneo Oda

Satoshi Yamamoto

Naoki Ishii

Junya Shirai

Shoji Fukumoto

Yoshiyuki Fukase

Yoshihide Tomata

Atsuko Ochida

Mitsunori Kono

Tomoya Yukawa

Shuichi Furuya

Hidekazu Tokuhara

Michiko Tawada

Takenori Hitaka

Kazuhiro Miwa

Masami Kusaka

Nobuo Cho

Nobuo Choh

Hirokazu Matsumoto

Hiroyuki Watanabe

Mitsuyoshi Azuma

Masaaki Hirose

Ayumu Sato

Yusuke Sasaki

Masanori Okaniwa

Chiho Fukiage

Kenichiro Naito

Toshiya Tamura

Yoji Hayase

Masami Kusuka

Takashi Toyama

Yoshiro Saito

Provided are heterocyclic compounds having a ROR&#x3b3;t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. wherein each symbol is as defined in the specification.

Heterocyclic compound

The problem of the present invention is to provide a compound having a superior ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The present invention provides a heterocyclic compound having a ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.or a salt thereof.

The present invention provides a compound represented by the formula: wherein Ris a Calkyl; Ris (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1') a halogen, (2&#x2032;) a hydroxy group, (3&#x2032;) a Calkyl and (4&#x2032;) a Calkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1&#x2032;) a halogen, (2&#x2032;) a Calkoxy-Calkyl, (3&#x2032;) a mono-Calkyl-carbamoyl-Calkyl, (4&#x2032;) a Calkoxy and (5&#x2032;) a mono-Calkylcarbamoyl-Calkoxy, or the like; Ris a Calkyl; Ris a Calkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.

Thienopyrimidine compounds and use thereof

Provided is a heterocyclic compound showing strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound and use thereof

Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof

The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, Ris a Caryl group which has substituent(s), and the like; Tis a single bond, a Calkyl group, &#x2014;CHO&#x2014;, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Zis a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a Caryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.

Bicyclic derivative, its production and use

The present invention provides a thienopyrimidine compound, represented by the formula  [wherein, Ris Calkyl, Ris (1) phenyl optionally having a substituent such as amino, mono Calkylamino and di Calkylamino, or (2) a heterocyclic group optionally having a substituent such as amino, mono Calkylamino and di Calkylamino and the like, Ris a hydrogen atom or Calkyl, Ris Calkyl optionally having a substituent such as Calkoxy-carbonyl, carboxyl, mono Calkylamino and N&#x2014;Calkyl-N&#x2014;Caralkylamino and the like] or a salt thereof, which has antagonistic action for gonadotropin-releasing hormone.

Thienopyrimidines, process for preparing the same and use thereof

The compounds of the present invention possess excellent gonadotropin-releasing hormone antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases, e.g., sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromyoma, endometriosis, precocious puberty, amenorrhea syndrome, multilocular ovary syndrome, pimples etc, or as a pregnancy regulator (e.g., contraceptive), infertility remedy or menstruation regulator.

Thienopyridine compounds, their production and use

Growing community of inventors

Kanagawa, Japan

Takashi Imada